3 Growth Stocks Set to Flourish

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Luckily for you, our job at StockStory is to help you avoid short-term fads by pointing you toward high-quality businesses that can generate sustainable long-term growth. Keeping that in mind, here are three growth stocks where the best is yet to come.

Toast (TOST)

One-Year Revenue Growth: +23.4%

Born from the frustrations of three friends waiting too long for their restaurant bill, Toast (NYSE:TOST) provides a cloud-based digital technology platform with software, payment processing, and hardware solutions built specifically for restaurants.

Why Could TOST Be a Winner?

1. ARR growth averaged 28% over the last year, showing customers are willing to take multi-year bets on its software
2. Sales outlook for the upcoming 12 months implies the business will stay on its desirable two-year growth trajectory

Toast is trading at $23.07 per share, or 1.7x forward price-to-sales. Is now a good time to buy? See for yourself in our full research report, it’s free.

CECO Environmental (CECO)

One-Year Revenue Growth: +32.1%

With roots dating back to 1869 and a focus on creating cleaner industrial operations, CECO Environmental (NASDAQ:CECO) provides technology and expertise that helps industrial companies reduce emissions, treat water, and improve energy efficiency across various sectors.

Why Will CECO Outperform?

1. Impressive 19.9% annual revenue growth over the last two years indicates it’s winning market share this cycle
2. Demand for the next 12 months is expected to accelerate above its two-year trend as Wall Street forecasts robust revenue growth of 23.9%
3. Performance over the past two years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue

CECO Environmental’s stock price of $86.64 implies a valuation ratio of 49.1x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Halozyme Therapeutics (HALO)

One-Year Revenue Growth: +39.1%

Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ:HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.

Why Do We Like HALO?

1. Market share has increased this cycle as its 32.2% annual revenue growth over the last two years was exceptional
2. Earnings per share have massively outperformed its peers over the last five years, increasing by 28.7% annually
3. HALO is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders

At $69.49 per share, Halozyme Therapeutics trades at 4.6x forward price-to-sales. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.

Stocks We Like Even More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.